Trial · NCT03107507
Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG
NCT03107507, Phase 4, Unknown, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG. Trials, record NCT03107507. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03107507
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG
- NCT number
- NCT03107507
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Cairo University
- Conditions
- Neonatal Seizures
- Interventions
- Levetiracetam, Phenobarbital
- First posted
- 2017-04-11
- Last updated
- 2017-04-11
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of levetiracetam in control of neonatal seizures as a first line versus phenobarbital through assessment of seizure burden. | 72 hours | Number of seizures before and after levetiracetam administration in comparison to phenobarbital. |
| Primary | Efficacy of levetiracetam in rapid control of neonatal seizures compared to phenobarbital. | 72 hours | Number of hours taken to achieve seizure freedom after administration of levetiracetam versus phenobarbital. |
| Secondary | Dose escalation data about levetiracetam through studying the efficacy of further dose administration in non responders. | 72 hours | Number of originally non responder participants who achieved seizure control with higher doses of levetiracetam. |
| Secondary | Adequacy of levetiracetam as a single agent antiepileptic drug in control of neonatal seizures. | 30 days | Number of participants who require addition of second line antiepileptic drug to control seizures after levetiracetam versus phenobarbital use. |
| Secondary | Accuracy of amplitude integrated EEG monitoring in detecting neonatal seizures before and after antiepileptic drug use. | 48 hours | Number of seizures detected by aEEG before and after antiepileptic drug use. |
| Secondary | Effect of levetiracetam on aEEG background activity of participants. | 48 hours | Number of participants with normalization of background activity after administration of levetiracetam versus phenobarbital. |
| Secondary | The short term clinical outcome of patients with neonatal seizures after treatment with levetiracetam. | 3 months | Neurodevelopmental assessment through detecting presence of following milestones: 1. Head control 2. Social smile 3. Visual fixation and pursuit 4. Turning towards sounds |
| Secondary | The short term electroencephalographic outcome of patients with neonatal seizures after treatment with levetiracetam | 3 months | Number of participants with presence of epileptogenic activity on follow up electroencephalogram. |
| Other | To gather safety information on levetiracetam use in neonates | 72 hours | By collecting data of renal and liver function tests 48-72 hours after treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03107507
GET https://conductscience.org/api/trials/v1/NCT03107507/registered